Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1947952

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1947952

Drugs for PrEP Market by Product Type, Administration Route, Distribution Channel, Mechanism Of Action - Global Forecast 2026-2032

PUBLISHED:
PAGES: 183 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Drugs for PrEP Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 8.26%, reaching USD 4.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 4.08 billion
CAGR (%) 8.26%

An orienting introduction to the dynamic PrEP prevention landscape, aligning clinical innovation with access and delivery realities

The prevention landscape for HIV pre-exposure prophylaxis (PrEP) is undergoing rapid transformation driven by therapeutic innovation, shifting care delivery models, and evolving payer and policy environments. Recent clinical advances have broadened the options available to individuals at risk, while health systems and community providers are adapting care pathways to improve uptake and persistence. Against this backdrop, stakeholders must reconcile the promise of long-acting modalities with the entrenched role of daily oral therapies, ensuring that clinical benefits translate into real-world access and equitable outcomes.

This introduction situates readers in the current environment, emphasizing the dual imperative of clinical efficacy and programmatic feasibility. It highlights how product characteristics, administration routes, and end-user needs intersect to shape decisions across manufacturers, payers, and providers. By framing the discussion around access, adherence, and delivery, the following sections explore the forces redefining PrEP strategy and offer a structured lens for evaluating investment, commercialization, and policy options. As the landscape evolves, organizations that align scientific innovation with pragmatic distribution and reimbursement tactics will be best positioned to expand prevention impact.

How clinical innovation, care delivery evolution, and payer policy are converging to drive transformative shifts across the PrEP ecosystem

The past several years have produced transformative shifts that are reshaping how PrEP is developed, delivered, and financed. A notable pivot toward long-acting injectable formulations has challenged the dominance of daily oral therapy by offering adherence advantages and novel service delivery opportunities. As evidence mounts for injectable agents in diverse populations, clinicians and health systems are reconsidering care models to support periodic clinic visits, injection administration, and monitoring, which in turn influences site-of-care economics and workforce planning. Concurrently, regulatory approvals and guideline updates have broadened indications and informed risk stratification, prompting payers to revisit formulary placement and prior authorization frameworks.

Beyond therapeutics, digital health and telemedicine have accelerated patient identification, initiation, and follow-up, bridging gaps created by geographic and social barriers. Community-based distribution and pharmacy engagement have expanded, enabling decentralized access while creating new partnerships between manufacturers and nontraditional channels. These converging trends underscore a shift from product-centric strategies to ecosystem-centric approaches, where success depends on coordinated clinical evidence generation, stakeholder alignment, and flexible distribution models that meet the needs of heterogeneous end users.

Assessing the cumulative operational and access implications of United States tariff shifts enacted in 2025 on PrEP supply chains and payer dynamics

The introduction of cumulative tariff changes in 2025 has introduced a new economic variable that affects supply chain design, procurement choices, and pricing strategies for PrEP products. Higher duties on imported active pharmaceutical ingredients, finished dosage forms, and packaging components increase landed input costs for both branded and generic producers, particularly when supply chains rely on cross-border sourcing of bulk materials. In response, manufacturers and contract manufacturers are evaluating nearshoring, vertical integration, and alternative sourcing strategies to protect margins and maintain supply reliability, while procurement teams reassess supplier diversification to mitigate concentration risk.

These trade measures also influence payer negotiations and formulary decision making. Where incremental cost pressures emerge, payers may tighten utilization management or accelerate value-based contracting conversations that tie reimbursement to adherence or clinical outcomes. Health systems that self-procure for hospital pharmacies and clinics face budgetary strain that can alter stocking practices and ordering cadence. At the same time, tariffs create an impetus for investment in domestic manufacturing capacity and bilateral trade agreements that could, over time, reduce exposure to external shocks. Overall, the policy environment introduced by 2025 tariffs highlights the need for strategic supply chain planning, transparent cost modeling, and collaborative approaches among manufacturers, payers, and health systems to preserve access to PrEP therapies.

Deep segmentation insight detailing how product type, administration route, end user, distribution channel, and mechanism of action jointly shape strategic choices

Segmenting the PrEP landscape reveals differentiated clinical, commercial, and operational implications that must guide strategy. Looking at product type, the landscape spans branded options-such as long-acting cabotegravir and established oral combinations-and generic formulations centered on TDF/FTC, each with distinct clinical profiles, patent trajectories, and pricing dynamics. These differences affect decisions about manufacturing scale, portfolio sequencing, and patient outreach, as branded long-acting agents may command premium positioning while generics drive broader accessibility.

When considering administration route, injectable therapies change the locus of care by requiring clinic-based encounters for long-acting dosing schedules, whereas daily oral regimens enable decentralized initiation and continuity through community and pharmacy channels. End user segmentation further refines targeting: prevention programs for men who have sex with men must integrate culturally competent outreach and rapid initiation pathways, while strategies for heterosexual adults and people who inject drugs require tailored adherence support, harm reduction alignment, and linkage to social services.

Distribution channel segmentation clarifies operational choices: hospital pharmacies play a critical role for clinic-administered injectables, online pharmacies expand reach for oral regimens, and retail pharmacies-both chain and independent-serve as essential access points for routine dispensing and patient counseling. Finally, mechanism of action distinctions-between integrase strand transfer inhibitors implemented as cabotegravir and nucleotide reverse transcriptase inhibitor options differentiated by TAF-based and TDF-based chemistries-inform clinical positioning, monitoring needs, and resistance stewardship. Together, these intersecting segmentations should drive differentiated commercialization, access planning, and evidence generation.

Regional lenses on access and adoption revealing how geographic variability in systems and financing drives differentiated PrEP deployment strategies

Regional dynamics significantly influence adoption pathways and operational priorities for PrEP interventions. In the Americas, a mature regulatory environment and established prevention programs coexist with persistent disparities in access; payer engagement and integrated care models drive uptake in urban centers, while community programs remain essential for reaching marginalized populations. Policy changes, procurement frameworks, and local manufacturing capacities further differentiate national responses across the region.

In Europe, Middle East & Africa, diversity in health system maturity and financing mechanisms produces heterogenous adoption patterns. High-income countries in Europe typically align guideline updates with systematic reimbursement pathways, enabling rapid incorporation of new modalities, whereas many countries in Africa and parts of the Middle East rely on donor programs, national guidelines, and task-shifting to scale preventive services. Supply chain resilience and affordability are central concerns, and partnerships with global procurement agencies often shape availability.

Across Asia-Pacific, a mix of large public programs, evolving private sector engagement, and variable regulatory timelines creates a nuanced landscape. Several countries are investing in domestic manufacturing and regulatory harmonization, which can shorten pathways for local supply, while others leverage private pharmacies and telehealth to expand access. Each region's structural characteristics-funding models, care delivery norms, and manufacturing footprints-should inform tailored strategies for product launch, distribution, and stakeholder engagement.

Key competitive and partnership insights highlighting how brand differentiation, generics, and distribution alliances determine real-world PrEP reach and uptake

Competitive dynamics in the PrEP arena reflect a balance between established brand owners, innovative modality entrants, and an expanding base of generic manufacturers. Brand owners that commercialize long-acting formulations have invested heavily in clinical development and provider education to support clinic-based administration, while companies with oral combination products have emphasized convenience, patient support programs, and broad pharmacy distribution. Generic manufacturers play a pivotal role in expanding affordability and access, especially in regions where procurement mechanisms prioritize cost containment and volume purchasing.

Partnerships between producers and distributors, plus collaborations with public health agencies and community organizations, increasingly determine real-world reach. Manufacturers that integrate demand generation with robust supply commitments, patient assistance frameworks, and clinician training gain traction across care settings. Additionally, innovators are exploring value partnerships with payers to align pricing with outcomes and adherence measures. Overall, competitive advantage accrues to organizations that combine clinical differentiation with pragmatic delivery models, resilient supply chains, and targeted stakeholder engagement across public and private channels.

Actionable recommendations for industry leaders to secure supply resilience, optimize delivery, and accelerate equitable access to PrEP innovations

Leaders across industry and policy spheres must translate insights into concrete actions to ensure sustained prevention impact. First, investing in diversified supply chains and dual sourcing for critical inputs will reduce exposure to trade policy shocks and preserve continuity of supply. Second, aligning product development with real-world delivery realities is essential; manufacturers should design clinical programs and packaging for ease of administration in both clinic and community settings, and develop adherence supports that reflect the needs of distinct end users.

Third, proactive payer engagement is critical to secure predictable access pathways. Early dialogue that links clinical value to outcomes and operational feasibility can streamline reimbursement and reduce initiation barriers. Fourth, distribution strategies need to be nuanced: integrating hospital pharmacies for injectable administration, leveraging online pharmacies for easier access to oral products, and partnering with chain and independent retail pharmacies for counseling and ongoing dispensing will broaden reach. Finally, public-private collaboration-spanning community organizations, health departments, and companies-can accelerate culturally competent outreach and retention, ensuring that scientific advances translate into equitable prevention outcomes.

Transparent, evidence-based research methodology that integrates stakeholder insights, regulatory review, and operational analysis to inform strategic decisions

The research underpinning these insights combined a multimodal approach centered on primary stakeholder engagement, clinical evidence synthesis, and operational analysis. We conducted structured interviews with clinicians, pharmacists, payer representatives, procurement officers, and patient advocates to capture frontline perspectives on prescribing behavior, adherence barriers, and channel dynamics. These qualitative inputs were triangulated with a systematic review of regulatory approvals, guideline revisions, and published clinical trial outcomes to ensure technical accuracy and relevance to current practice.

Operational dimensions relied on supply chain mapping, procurement process examination, and scenario analysis of policy developments such as tariff adjustments. Comparative case studies across different health systems informed regional differentiation and distribution channel assessment. Throughout, methodological rigor emphasized transparent data sourcing, cross-validation of interview findings with publicly available regulatory documents, and iterative expert review to refine interpretations. This blended methodology supports conclusions that are both evidence-based and pragmatic for decision makers seeking to translate insights into operational strategies.

Concluding synthesis that integrates clinical advances, delivery imperatives, and policy considerations to guide pragmatic PrEP decision making

In conclusion, the PrEP landscape is in a state of strategic transition driven by therapeutic innovation, evolving care models, and shifting policy levers. Long-acting injectables introduce promising adherence and retention advantages but require reconfigured delivery pathways and payer engagement to realize their full potential. Daily oral formulations remain indispensable for broad, decentralized access, especially where pharmacy and online channels facilitate initiation and persistence. The interplay of product type, administration route, end-user needs, distribution channels, and mechanism of action creates a complex but navigable decision matrix for manufacturers, payers, and providers.

External factors, including trade policy changes and regional system characteristics, add urgency to supply chain diversification and stakeholder collaboration. Organizations that align clinical differentiation with pragmatic distribution strategies, robust payer engagement, and culturally competent outreach will be best positioned to expand prevention coverage. Ultimately, converting scientific progress into population impact requires coordinated action across the commercial, clinical, and public health spheres to ensure that effective PrEP options reach those who can benefit most.

Product Code: MRR-4F7A6D4FB6A2

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for PrEP Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Apretude
    • 8.1.2. Descovy
    • 8.1.3. Truvada
  • 8.2. Generic

9. Drugs for PrEP Market, by Administration Route

  • 9.1. Injectable
  • 9.2. Oral

10. Drugs for PrEP Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain Pharmacy
    • 10.3.2. Independent Pharmacy

11. Drugs for PrEP Market, by Mechanism Of Action

  • 11.1. Integrase Strand Transfer Inhibitors
  • 11.2. Nucleotide Reverse Transcriptase Inhibitors

12. Drugs for PrEP Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drugs for PrEP Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drugs for PrEP Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drugs for PrEP Market

16. China Drugs for PrEP Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol Myers Squibb Company
  • 17.10. Cipla Limited
  • 17.11. Emcure Pharmaceuticals Limited
  • 17.12. Gilead Sciences, Inc.
  • 17.13. GlaxoSmithKline plc
  • 17.14. Hetero Labs Limited
  • 17.15. Janssen Pharmaceuticals, Inc.
  • 17.16. Lupin Limited
  • 17.17. Macleods Pharmaceuticals Ltd.
  • 17.18. Merck KGaA
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi SA
  • 17.23. Sun Pharmaceutical Industries Ltd.
  • 17.24. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4F7A6D4FB6A2

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!